We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » More Restructuring for Merck as Key Product Patents Expire
More Restructuring for Merck as Key Product Patents Expire
October 4, 2013
Facing significant patent cliff pain, Merck said Oct. 1 it plans to refocus its research around new therapies that present the “best opportunities:” vaccines, oncology, diabetes and acute care.